Prostate Cancer / 2017 / Article / Tab 1 / Research Article
Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis Table 1 All studies included in analysis.
Author/study PMID Clinical trial code Treatment Race Age Gleason score ≥ 8 Baseline PSA (median) PSA decline ≥ 50% Thortzen et al. 26971191 45 AX White 71.3 60% 156 51% Poon et al. 27001043 58 AX Asian 77.0 28% 212 62% Suzman et al. 25053178 30 AX White 70.6 48% 192 34% Kim et al. 25336698 39 AX White 71.0 48.5 41% COU-AA-302 23228172 NCT00887198 546 AX White 70.5 29% Yamasaki et al. 26722066 51 EX Asian 74.0 78% 11.2 63% Higano and Crawford 25698064 65 EX White 68.0 35 63% TERRAIN 26774508 NCT01288911 184 EX White 70.3 55% 21 82% STRIVE 26811535 NCT01664923 198 EX White 72.0 51% 11 81% PREVAIL 25888263 NCT01212991 872 EX White 71.3 51% 54.1 78% Kwak et al. 25099185 82 DA Asian 71.0 74% 124.3 49% Ferraldeschi et al. 25454616 57 DA White 66.0 41% 155 32% COU-AA-301 23142059 NCT00638690 797 DA White 69.0 51% 27 38% Praet et al. 26850781 368 DA White 73.0 103 37% Poon et al. 27001043 52 DA Asian 66.0 56% 191 50% Thortzen et al. 26971191 28 DA White 70.7 71% 169 18% Caffo et al. 24988879 265 DA White 73.0 51% 86 50% Burgio et al. 24999168 103 DA White 74.0 53% 32.5 Ferraldeschi et al. 25454616 87 DA White 69.0 55% 237 43% Qu et al. 27489290 81 DA White 49% 16.4 Conteduca et al. 27434372 193 DE White 73.1 51% Yamasaki et al. 26722066 40 DE Asian 83% 23 44% Higano and Crawford 25698064 75 DE White 68.0 64 53% AFFIRM 22894553 NCT00974311 800 DE White 68.8 50% 107.7 54%
The studies that provided two cohorts for our analyses are denoted ( ) and correspond to those in Figures 2 and 3 . Race is the predominant proportion within each cohort and age is either a mean or median measure. Blank cells indicate a lack of reporting in that category.